SCHEMBL25568446

SCHEMBL25568446

CC1(CNC(=O)OCc2ccccc2)CC(NC(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.49
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 2/20 0.46
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.44
KLK7 P49862 2/20 0.44
KLK5 Q9Y337 2/20 0.44
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
ACHE P22303 2/20 0.43
EPHX1 P07099 1/20 0.43
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
RORC P51449 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30772707 0.83 ALDH1A1 (0.52) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL17864855 0.83 TSHR (0.62) KMT2AALDH1A1GAATSHRMEN1
SCHEMBL3944460 0.82 ALDH1A1 (0.69) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL6153463 0.82 ALDH1A1 (0.69) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL3944464 0.82 ALDH1A1 (0.69) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL30994175 0.81 KMT2A (0.52) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL4929457 0.80 ALDH1A1 (0.62) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL14010470 0.80 ALDH1A1 (0.62) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL2291956 0.80 ALDH1A1 (0.62) SYKKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL4929443 0.80 ALDH1A1 (0.62) SYKKMT2AL3MBTL1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME LLC (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159517-A1 CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS TCOF1, SLC10A2, PAM SYK 567/4885KMT2A 2833/4885L3MBTL1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.